



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Total Voting Rights**

**London: Friday, 28 September 2012:** For information purposes, Chi-Med hereby notifies the market that as at 28 September 2012, the issued share capital of the Company consisted of 52,048,448 ordinary shares of US\$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 52,048,448 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the FSA's Disclosure and Transparency Rules.

**Ends**

**Enquiries**

**Chi-Med** Telephone: +852 2121 8200  
Christian Hogg, CEO

**Citigate Dewe Rogerson** Telephone: +44 20 7638 9571  
Anthony Carlisle Mobile: +44 7973 611 888  
David Dible Mobile: +44 7967 566 919

**Panmure Gordon (UK) Limited** Telephone: +44 20 76148383  
Richard Gray  
Andrew Potts  
Grishma Patel

**About Chi-Med**

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.